Interferons control viral replication and the growth of some malignant tumors. Since systemic application may cause severe adverse effects, tissue-specific expression is an attractive alternative. Liver-directed interferon gene therapy offers promising applications such as chronic viral hepatitis B or C or hepatocellular carcinoma and thus needs testing in vivo in suitable animal models. We therefore used the Tet-On system to regulate gene expression in adenoviral vectors, and studied the effect of liver-specific and regulated interferon g expression in a mouse model of chronic hepatitis B virus (HBV) infection. In a first generation adenoviral vector, genes encoding for firefly luciferase and interferons a, b or g, respectively, were coexpressed under control of the bidirectional tetracycline-regulated promoter P tet bi. Liverspecific promoters driving expression of the reverse tetracycline controlled transactivator ensured local expression in the livers of HBV transgenic mice. Following gene transfer, we demonstrated low background, tight regulation and a 1000-fold induction of gene expression by doxycycline. Both genes within the bidirectional transcription unit were expressed simultaneously, and in a liver-specific fashion in cell culture and in living mice. Doxycycline-dependent interferon g expression effectively controlled HBV replication in mice, but did not eliminate HBV transcripts. This system will help to study the effects of local cytokine expression in mouse disease models in detail. Gene Therapy (2005) 12, 668-677.
Introduction
Tightly regulated and tissue-specific gene expression is a major goal in studies aiming to explore gene function but also when toxic or potentially toxic agents offer the only treatment options for certain diseases. In the latter case, conditionally activated and local expression of the drug in the target tissue may help to avoid severe side effects observed following systemic application.
Potentially toxic transgenes such as cytokines or proapoptotic genes are candidates for the treatment of infectious diseases and malignant liver diseases. Recombinant interferon (IFN) alpha (IFNa) is the current treatment of choice for chronic hepatitis B and C. Its therapeutic efficacy, however, is limited by severe side effects observed following systemic application, which cause the withdrawal of many patients from therapy. IFN gamma (IFNg), tumor necrosis factor alpha, interleukin-12 and interleukin-18 were also shown to very effectively control replication of hepatitis B virus (HBV) [1] [2] [3] or hepatitis C virus, 4 but clinical application of these cytokines is hindered by potential toxicity following systemic application. However, there is good chance to avoid toxicity by regulated, local expression in the liver following gene transfer. 5 The tetracycline-regulated (Tet) gene expression system developed by Gossen and Bujard, 6, 7 is widely used to control gene expression in vitro and in vivo. In the Tet system, control elements of the tetracycline-resistance operon of Escherichia coli were converted into eukaryotic transcription activation elements: the E. coli Tet repressor fused to a eukaryotic transactivation domain binds to a seven-repeat Tet-operator sequence controlling a minimal CMV promoter (P tet ). This principle is employed in two ways: in the Tet-Off system, tetracycline derivative doxycycline (Dox) binds to the tetracycline-controlled transcriptional transactivation domain (tTA) and prevents binding of tTA to P tet and thus its activation; 6 in the Tet-On system, binding of Dox to a mutated and thus reverse tTA (rtTA) is required to induce transcription. 7 Fusion of a second minimal CMV promoter element to P tet generates a bidirectional, tTA/rtTA responsive promoter (P tet bi) that allows simultaneously regulated expression of two genes. 8 Using the Tet-system, tissue specificity can be obtained by directing the expression of tTA or rtTA to the desired organ using tissue-specific promoters. 9, 10 Recently, new rtTAs were identified, which function at lower Dox concentrations, and therefore are more stable in eukaryotic cells and efficiently reduce background expression in the absence of Dox. 11 The Tet system is widely used to study gene function and to generate conditional mutants in cell lines and in transgenic animals (reviewed in: Baron and Bujard 12 and Gossen and Bujard 13 ). It has also been used to generate regulated gene delivery vectors based on adenoviruses, [14] [15] [16] [17] adeno-associated virus, [18] [19] [20] retroviruses, 21, 22 lentiviruses 23, 24 and herpes simplex virus. 25 We therefore decided to use the Tet system to obtain a regulated, local expression of IFNs in the liver, and to study the effect on HBV replication in vivo in a transgenic mouse model.
We employed adenoviral vectors because they are highly efficient as vehicles for delivery and expression of transgenes in the liver. First-generation replicationdefective adenovirus 5 vectors were generated and tested for tightly regulated interferon gene expression in cell culture and in vivo in mice. Using these vectors, we obtained liver-specific and regulated IFNg gene expression that allowed efficient control of HBV replication in transgenic mice.
Results

Description of the Tet-regulated adenoviral vectors
To establish a Dox-dependent gene expression system with adenoviral vectors, we inserted into the E1 deletion of adenoviral transfer plasmid pShuttle 26 a cassette that contained a firefly luciferase (luc) reporter gene with a deleted PacI site and an SV40 late polyadenylation site (A n1 ) under control of P tet bi. 8 A multiple cloning site (MCS: MluI, SalI, HindIII, XhoI, NotI) was created to allow insertion of transgenes under the same bidirectional promoter upstream of a polyadenylation signal of the rabbit b-globin gene (A n2 ) (Figure 1 ). The resulting transfer plasmid was used to generate first generation adenovirus type 5 vectors (Ad5DE1DE3) by recombination with an E3-deleted adenoviral backbone plasmid in E. coli 26 (all adenoviral plasmids were kindly provided by TC He and B Vogelstein).
The cassette was inserted in either direction obtaining vectors Adbiluc or Adbiluc2 to test whether adenoviral regulatory elements contained in the vector backbone may influence regulation or tissue specificity. 27, 28 To obtain liver specificity of gene expression, the tTA/ rtTA was expressed under control of the liver-activated protein promoter (P LAP   29 ) in transgenic mice, 9, 30 or under control of the transthyretin promoter (P TTR 31 ) in stably transfected HuH7 hepatoma cells. To obtain tight regulation and stable expression using the Tet-On system, we employed the recently described synthetic rtTA2 S -S2.
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The luc reporter allowed sensitive and quantitative detection of gene expression as well as noninvasive bioluminescence imaging in living mice. 10 Insertion of a green fluorescent protein (GFP) gene into the MCS generated vector Adbiluc-GFP and allowed one to determine the amount of transduced cells. Insertion of mouse IFNa, b and g cDNA generated vectors AdbilucmIFNa, Adbiluc-mIFNb and Adbiluc-mIFNg and allowed one to investigate the expression of the respective interferon locally in the liver.
Dox-induced luciferase activity in liver cell culture following adenoviral gene transfer
To determine basal expression of luciferase from our adenoviral vectors, we infected human hepatocellular carcinoma cells HuH7 with Adbiluc and Adbiluc2 at moi 5 and 10 infectious units (i.u.) per cell and added 1 mg/ml Dox. No luciferase activity was detected in cell lysates of transduced HuH7 cells ( Figure 2 ) when a Tet-transactivator was lacking.
In addition, we isolated primary human hepatocytes as described recently 32 and infected them with the Adbiluc and Adbiluc2. Infection with adenoviral vectors at moi 3 i.u./cell usually is sufficient to transduce all primary human hepatocytes.
32 Using Adbiluc2, a moi of 1, 5 and 10 i.u./cell resulted in a luciferase activity of 471, 2077 and 38720 (mean7s.d.) relative light units (RLU) per microgram total protein. Thus, background expression of luciferase was very low following transduction of primary human hepatocytes with Adbiluc2. Using Adbiluc accordingly, 55728, 84715 and 120773 RLU/mg total protein, respectively, was determined indicating higher background expression (data not shown).
To be able to monitor Dox-induced gene expression in vitro in liver cells, we generated an HuH7 cell line that stably expressed rtTA S -S2 under control of the liverspecific TTR promoter (HuH7-TTR-rtTA). HuH7-TTRrtTA cells were infected with 0.5 to 10 i.u./cell of Adbiluc and Adbiluc2. Gene expression was induced by addition of 1 mg/ml Dox, and luciferase activity in the cell lysate was determined in comparison with untreated cells.
In the presence of rtTA S -S2, a low basal expression of luciferase was detected without addition of Dox, which increased proportional to the amount of transcription templates available (Figure 2 ). Basal expression in cells transduced with Adbiluc was slightly higher than in cells transduced with Adbiluc2. Following addition of Dox, luciferase expression was induced 118-to 665-fold from Adbiluc and 735-to 986-fold from Adbiluc2 ( Figure 2) . From these results, we concluded that background expression from P tet bi was primarily due to the presence of rtTA. Liver-specific interferon c expression in HBV transgenic mice J Dumortier et al However, in addition, we observed an influence of adenoviral regulatory elements on the minimal CMV promoter. If the minimal promoter P tet bi was inserted in proximity of adenoviral enhancers located on the adenoviral genome, basal activity was observed (as in Adbiluc). If the distance was increased by inserting the cassette in the opposite direction (as in Adbiluc2) or by inserting a second gene (as in AdbilucGFP), gene expression was more tightly regulated.
This was even more evident, when TA LAP -2 mice 9 (TetOff system) were infected with 2.5x10 9 i.u. of either adenovirus Adbiluc (n ¼ 5), Adbiluc2 (n ¼ 6) or Adbiluc-GFP (n ¼ 7) via the tail vein, and their livers were analyzed. In the animals infected with Adbiluc2 or Adbiluc-GFP, no basal luciferase expression (o2 RLU/mg protein) was detected, but in animals infected with Adbiluc, low basal expression 12-17 RLU/mg protein) was detected in the 'off' state. In mice analyzed in the 'on'-state, luciferase expression was induced 10 2 -to 10 5 -fold (data not shown).
As a consequence of this analysis, we inserted IFN genes for therapeutic purposes under control of bidirectional promoter P tet bi of an Adbiluc vector containing a large luciferase expression cassette to minimize their background expression.
Repeated turning on and off gene expression in mice following adenoviral gene transfer Analysis of liver tissue sections in the 'on' state showed that 495% of mouse hepatocytes were successfully transduced and expressed GFP when 2.5 Â 10 9 i.u. Adbiluc-GFP was injected via the tail vein (Figure 3a) . By fluorescence microscopy, GFP expression was easily detected in the liver but not in other tissues. In addition, the liver, kidney, spleen, heart, muscle, brain, and lung tissues of four mice, each in the 'on' and 'off' state, were lysed and luciferase activity was determined. In the 'off' state, no luciferase activity was detected in these organs; in the 'on' state, luciferase activity was detected only in the kidney and liver (data not shown). Induction of gene expression in the kidney was explained by a residual activity of promoter P LAP in the kidneys of transgenic mice, which results in an expression of the Tettransactivator. 9, 33 However, expression levels in the liver were 80-fold higher than in the kidney and more than 1000-fold higher than in the spleen, heart, muscle, brain or lung, proving the liver specificity of the system.
Luciferase luminescence can be detected in living animals using an intensified charged coupled photoncounting device camera and an image processor when the substrate is provided. 10, 34 To test whether gene expression can be repeatedly turned on and off following adenoviral gene transfer in vivo, we employed this noninvasive bioluminescence imaging technique.
Five male rTA LAP -1 mice (Tet-On system) were infected with 2.5 Â 10 9 i.u. Adbiluc-GFP by tail vein injection. In serial bioluminescence imaging examination, we studied induction and regulation of luciferase gene expression by Dox. No signal was detected in five mice 2 days postinfection with 2.5 Â 10 9 i.u. Adbiluc-GFP without Dox when luciferin substrate was provided, but strong luminescence was detected in the livers of all mice three days after initiation of Dox treatment (Figure 3b ).
When Dox was removed from drinking water, luciferase expression was turned off in all mice (day 9). However, it was reinduced to high levels (4721 and 141 642 RLU/mg protein) in two mice treated with Dox a second time (Figure 3b , lower panel, day 15). Thus, we had proven that repeated turning on and off of a Doxregulated expression cassette transferred by an adenoviral vector was possible.
Simultaneous expression of interferons and luciferase upon induction with Dox in a dose-dependent fashion
To generate vectors for a transfer of murine IFN (mIFN)a, b or g genes, we inserted the respective cDNA into the To determine if both genes expressed under control of the bidirectional promoter P tet bi were regulated with comparable kinetics, we transduced HuH7-TTR-rtTA cells with Adbiluc-mIFNg at a moi of 10 i.u./cell, and induced gene expression by addition of Dox at increasing concentrations from 0.01 to 1.5 mg/ml (Figure 4b ). After 48 h, secreted mIFNg was quantified in the cell culture medium by enzyme-linked immunosorbent assay (ELI-SA) and luciferase activity was determined in cellular extracts. As expected using this construct, no basal expression of IFNg was detected. Addition of increasing amounts of Dox resulted in a corresponding increase of luciferase activity and of mIFNg secretion. Maximal luciferase activity (500 06171413 RLU/mg protein) and mIFNg secretion (55.174.3 ng/ml) were obtained at 1.2 mg Dox per ml (Figure 4b ). This experiment demonstrated coregulation of both genes.
Tightly controlled expression of functional interferons in vivo
To verify coexpression in vivo in the liver, we infected groups of six rTA LAP -1 mice intravenously with 2 Â 10 8 i.u. Adbiluc-mIFNa, Adbiluc-mIFNb, or Adbiluc-mIFNg. Three mice each were kept without ('off'-state) or with supplementation of 2 mg/ml Dox in their drinking water ('on'-state). Four untreated mice served as controls. Following induction of gene expression for five days, livers were collected, luciferase activity was measured and expression levels of IFN-induced protein 10 (IP-10) and 2 0 5 0 oligoadenylate synthetase (2 0 5 0 OAS) were determined by real-time RT-PCR analysis. Levels of alanine transaminase (ALT) in the serum were monitored as an indicator for liver cell damage.
In all mice, luciferase expression was induced in the 'on'-state and an increase in liver IP-10 and 2'5'OAS mRNA levels was observed (Figure 4c ). ALT levels were maximally three-fold elevated, indicating low toxicity. Unexpectedly, in Adbiluc-mIFNa transduced mice, luciferase expression levels were 10-fold higher than in the other mice, and significant basal expression was observed in the 'off' state. Variations in the amount of input vector titers were excluded by repeated titrations. Taken together, we showed that functional mIFNa, b, and g were secreted from hepatocytes transduced with respective Adbiluc vectors upon addition of Dox.
Suppression of hepatitis B virus replication by expression of IFNg in the liver
To test the effect of IFNg expression in the liver on HBV replication, we used mice double transgenic for HBV and for the rtTA. In all, 12 animals were injected with Adbiluc-mIFNg, two uninfected and untreated mice served as controls. After 2 days, groups of three mice Serum ALT levels were up to three-fold elevated in all Adbiluc-mIFNg-treated animals, irrespective of whether they received Dox or not. Activation of IP-10 expression confirmed expression of functional IFNg in the 'on' state. Mean values are given for each group (Figure 5a ). Total DNA was extracted from pooled liver lysates (50 mg tissue per animal). In all, 20 mg DNA each was digested with HindIII and subjected to Southern blot analysis using a 32 P-labeled HBV-DNA probe to analyze HBV replication in the liver. Since HindIII restriction sites flanked the HBV transgene in these animals, the excised fragment shows that the HBV transgene is not affected and is able to serve as control, which ensures loading of equal amounts of DNA. When IFNg expression had been turned on, no HBV DNA replicative intermediates (ri) were detected anymore. Northern blot analysis of mRNA extracted from pooled liver lysates, however, showed no difference in HBV transcripts (Figure 5a ). HBV serum titers (mean values as determined by real-time PCR) dropped 6.5-to 20-fold in Dox-treated animals. of Adbiluc-mIFNg per mouse. Doxycycline was added to the drinking water at increasing doses ranging from 0.3 to 3 mg/ml from day 2 on to groups of three mice each matched for sex, age and serum level of HBeAg. Two uninfected and untreated animals served as control. At day 11 p.i., mice were sacrificed, and sera and liver tissues were analyzed. (a) DNA was isolated from pooled livers from each group of mice. In all, 20 mg of total liver DNA was digested with HindIII and subjected to Southern blot analysis with a 32 P-labeled HBV-specific DNA probe (upper blot). mRNA purified from 250 mg of total RNA extracted from pooled liver lysates was subjected to Northern blot analysis and detected accordingly. Bands corresponding to the integrated transgene (transgene), HBV replicative DNA intermediates (HBV DNA ri) and HBV genomic and subgenomic RNAs (HBV RNA) are indicated. Liver IP10 mRNA expression (cDNA copies per ml RNA), and serum HBV DNA titers and ALT activities were determined in pooled material from each group of mice. of Adbiluc-mIFNa, Adbiluc-mIFNb or Adbiluc-mIFNg, respectively. Three mice each received 2 mg/ml Dox with their drinking water (on). After 6 days, luciferase activity (RLU/mg protein) was determined in liver lysates, expression of interferon-induced genes was quantified using real-time RT-PCR analysis (given as cDNA copies/ml RNA), and levels of alanine aminotransaminase (ALT) were measured in mouse sera. Mean values and standard deviations obtained for each group of three mice and three untreated control mice are given.
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To control for the effect of Dox and Dox-induced expression of luciferase on HBV replication, we injected six double transgenic mice with 2 Â 10 8 i.u. of an Adbiluc vector, treated three of these and two uninfected mice with Dox, and analyzed HBV replication as described above. In these animals, HBV viremia was unchanged, and intrahepatic HBV replication was readily detectable (data not shown).
Histological analysis of the liver tissue samples (Figure 5b, left panel) showed a mild to moderate inflammatory response in Dox-treated animals with lymphocyte infiltration, single necroses and hepatocyte apoptosis. Immunohistology for HBV core protein (Figure 5b, right panel) showed cytoplasmic core staining, indicating active HBV replication in control animals as well as in Adbiluc-IFNg injected animals in the off state. However, no cytoplasmic core staining and a reduced number of hepatocytes with nuclear core staining were detected in Dox-treated animals.
Taken together, Dox-induced expression of IFNg following adenoviral gene transfer efficiently suppressed HBV replication in HBV transgenic animals without causing significant liver damage. However, HBV transcripts remained unaffected.
Discussion
To broaden the range of application of gene therapy, and to allow, for example, treatment of slowly progressing infectious diseases, it is necessary to use systems that allow controlling expression of the delivered transgene. 35 Tight control is especially needed when potentially toxic transgenes are delivered. The ideal regulatory system is turned on by application of an exogenously added small molecule ligand, should have no basal activity in the absence of the ligand ('off'-state), promote high expression levels in the 'on'-state and allow multiple switching between the 'on' and the 'off'-state. 36 In addition, tissue-specific gene expression is desired to minimize unwanted effects. Among the various regulatory systems available, the Tet system seems most suitable to fulfill these criteria. 12 Our aim was to develop a convenient and efficient delivery system for a liver-directed transfer of interferongenes, which allows studying the effects of liver-specific and regulated cytokine gene expression on replication of hepatitis B viruses in vivo. We employed adenoviral vectors because they are the most efficient vehicles for a liver-directed gene transfer available at the moment 37, 38 and allow regulating transgene expression in vitro and in vivo. 14, 15, 39 In our experiments, we employed first-generation adenoviral vectors. Following insertion into the adenoviral E1 region, a minimal basal activity of P tet bi was observed when no Tet-transactivator was present. However, the level of basal activity depended on the adenoviral construct used, and it rose in the presence of the rtTA (Figures 2 and 5) . It therefore appears that a basal activity of P tet bi may be due to two reasons: a low residual binding capacity of the rtTA and a crosstalk of adenoviral enhancer elements with the minimal promoter element.
The use of viral vectors, which contain viral cis-acting regulatory elements, bears the risk that these elements influence regulation of transgene expression. The activity of a metal-inducible promoter 27 and P tet 28 cloned into the E1-region of an adenoviral vector was reported to be affected by 3 0 and 5 0 adenoviral enhancer elements. However, all available adenoviral vectors contain the left ITR and the strong E1A enhancer, which cannot be removed due to overlaps with cis-acting sequences necessary for packaging. Our experiments confirmed an influence of adenoviral regulatory elements, but at the same time showed that proper design of the vector can minimize this influence. In our hands, the use of a bidirectional expression cassette proved advantageous, because transgenes shed the minimal promoter from 3 0 and 5 0 adenoviral enhancers. To avoid possible crosstalk between the enhancers of P LAP or P TTR and P tet , 25, 40 we did not integrate other promoters in close proximity to the regulated expression cassette. Thus, we did not include a second expression cassette for the Tet-transactivator on the same vector, but rather took the disadvantage into account that we had to work with transgenic animals or stably transfected cell lines. As a consequence, our work provides a proof-of-principle that expression of IFNg in the liver is able to suppress HBV replication, and shows an elegant system to study the molecular mechanisms of this antiviral effect in detail rather than providing a gene therapy that can be readily translated into the clinics.
In most of the earlier studies, the Tet-Off system was employed, because the original rtTA 7 showed a certain basal activity. For gene therapy applications, however, the Tet-On system is advantageous. Since modified rtTAs, rtTA2 s -M2 and rtTA2 s -S2, which are more stable in eukaryotic cells and cause lower background expression in the absence of Dox in vivo, 41 are now available, 11 we decided to use the Tet-On system to study interferon gene expression. The rtTA2 s -S2 has been reported to confer tight regulation when used in a helper-dependent adenovirus. 17 We observed a low residual binding affinity of rtTA2 s -S2 to P tet bi in the absence of Dox, indicating a defined background activity on adenoviral episomes. This activity is not observed when P tet bi controlled transcription units are embedded in favorable genomic loci, 30 indicating the influence of chromatin on transcription regulation.
In our cell culture experiments, adenoviral transduction of a Tet-regulated expression cassette led to highly reproducible expression levels. In vivo in transgenic mice, however, we observed a higher variability and gene expression was induced between 1000-and 100 000-fold. The variability observed may have different reasons: firstly, the level of rtTA expression in the livers of different animals may vary; secondly, transduction efficiencies may vary between different mice, and thirdly, the amount of doxycycline ingested may vary although we used a dose (2 mg/ml) that had proven sufficient to bind the rtTA. 42 In comparison to vectors containing GFP, mIFNb, or mIFNg transgenes, we observed a two-to five-fold increased basal level of transgene expression in mice infected with Adbiluc-mIFNa (Figure 4 ). This may be due to IFN responsive elements located in the linker regions between the heptametrical Tet operator sequences in P tet , 43 which in novel versions of this promoter have been eliminated (H Bujard, unpublished results).
Liver-specific interferon c expression in HBV transgenic mice J Dumortier et al Cytokine gene therapy offers many promising applications such as chronic viral hepatitis B or C or hepatocellular carcinoma. Cytokines such as IL-2, IFNg, or IL-12, however, are not well tolerated. In addition, there is genetic heterogeneity in the toxicity to systemic application of cytokines. 44 To be able to apply potentially toxic cytokines, regulated gene expression has been employed. For example, retrovirus-mediated regulated IL-2 expression suppressed growth of melanoma cells in mice. 45 A Dox-regulated adenovirus vector expressing the cytokine interleukin-12 46 was used to treat prostate cancer. A helper dependent vector expressing IFNa in a regulated fashion was used to prevent infection with mouse hepatitis virus. 17 We used adenoviral vectors to deliver an IFNg gene expressed in a Tet-regulated and liver-specific fashion and studied the effect in a hepatitis B mouse model. 1 It has been reported that an adenoviral gene transfer may induce IFN type I early after infection and an antiadenoviral immune response, which may influence HBV replication. 47 To avoid studying these side effects instead of studying the effect of IFNg on HBV replication, we always compared animals that had all received the same amount of adenoviral vectors. In addition, we used relatively low doses (2 Â 10 8 i.u./animal) of IFN-expressing vectors and the analysis was performed late (eleven days) after infection. Accordingly, we did not observe an expression of 2 0 5 0 OAS, a type I IFN-induced gene, after IFNg gene transfer if IFNg expression was not induced (Figure 4c ).
Upon expression of IFNg, HBV replication in the liver was almost completely suppressed. In contrast, the amount of the HBV transgene, which serves as a transcription template to initiate HBV replication, as well as HBV transcripts remained unaffected, indicating that HBV replication is blocked by IFNg at a posttranscriptional step. 48, 49 Low doses of Dox (0.3 mg/ml) were sufficient to induce IFNg expression and to block HBV replication, and even 10-fold higher doses (3 mg/ ml) had no additional effects. Since the addition of Dox to the drinking water was the only difference between mice in the 'on' and in the 'off' state, and since a treatment with Dox alone had no effect on HBV replication, the drastic effect on HBV replication was clearly due to IFNg expression.
Histological investigation of liver tissues of treated and untreated animals confirmed that IFNg is able to control HBV replication in a noncytopathic fashion. 1 Cytoplasmic staining of HBV core completely disappeared in Dox-treated animals, which seems to reflect the disappearance of HBV replication, and nuclear core accumulation was reduced. Since aggregates of core protein in the nucleus are very stable, a complete degradation during the relatively short experimental period was not expected. Serum viremia also dropped significantly, but the effect was less pronounced than that on intrahepatic replication. This may reflect the long halflife of virus due to missing neutralizing antibodies in the transgenic animals, or the envelopment and release of preformed viral capsids to fill up the serum pool. 50 Since HBV transcripts remained unaffected by IFNg expression in our experiments, we tried to increase the amount expressed by increasing the dose of the vector in subsequent experiments. However, when we increased the vector dose by a factor of two or more, animals died due to side effects of systemic IFNg distribution. Thus, we think that virus elimination will probably not be obtained by IFNg gene therapy alone, and that for therapeutic purposes this approach will have to be combined with other approaches.
Taken together, we developed an easy-to-use adenoviral vector system that allowed one to monitor regulated cytokine gene expression, and study the effects of liver-specific cytokine expression in vivo. Tight regulation was obtained if the bidirectional P tet bi was used, and a transgene was inserted as a spacer between adenoviral enhancers and the tetracycline-regulated promoter. Using this system to express IFNg in the livers of HBV transgenic mice, HBV replication was controlled upon application of Dox. This system will allow further studying conditional, local cytokine expression as a potential therapeutic approach of various liver diseases, and will allow to elucidate the molecular mechanisms involved in control of HBV by the immune system.
Materials and methods
Plasmid constructs and cDNAs used
Sequence for rtTA2 S -S2 was kindly provided by S Urlinger and W Hillen (University of Erlangen, Germany). Adenoviral plasmids pShuttle and pAdEasy1 26 were kindly provided by TC He and B Vogelstein (Howard Hughes Medical Institute, Baltimore, USA). The GFP cDNA originally derived from plasmid pTR-UF5 (kindly provided by Dr N Muzyczka) was excised from plasmid pCD16-S-GFP. 5 Plasmid pMPSVHEmuIFNb containing murine IFNb cDNA was kindly provided by H-J Hacker (GBF, Braunschweig, Germany). Plasmids pORF-mIFNav1.1andpORFmIFNgcontainingmurineIFNa and g cDNA, respectively, were obtained from InvivoGen, San Diego, USA. By PCR, restriction sites SalI (5 0 ) and HindIII (3 0 ) were added to mIFN cDNAs using appropriate primers that allowed cloning into the multiple cloning site of pAdbiluc (Figure 1 ).
Cell lines
Cells were maintained in Dulbecco's minimum essential medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 50 IU/ml of penicillin and 50 mg/ml of streptomycin at 371C in 5% CO 2 . To cultivate HuH7 hepatoma cells, 1 mM sodium pyruvate and nonessential amino acids were added. Primary human hepatocytes were isolated and cultivated as described.
32, 51 For all experiments, tetracycline-free serum was used (BD Biosciences Clontech, Paolo Alto, CA, USA). A human hepatoma HuH7 cell line constitutively expressing rtTA2 S -S2 11 was generated by cotransfection of plasmids pUHD-0,6-TTR-rtTA and pSV2neo in a ratio 30:1 using the calcium phosphate method. Plasmid pUHD-0,6-TTRrtTA expresses the rtTA2 S -S2 under control of the liverspecific P TTR , 31 and plasmid pSV2neo confers neomycin resistance. A total of 40 clones resistant to G418 (500 mg/ ml) were isolated and assayed for expression of rtTA2 S -S2 by transient transfection with luciferase reporter plasmid pBi-2.
8 Clone 3 was selected because of low background and high induction rate and expanded to generate cell line HuH7-TTR-rtTA. 52 To generate double transgenic mice, rTA LAP -1 mice and HBV1.3xfs mice were bred homozygously and crossed with each other. Offspring that were heterozygous for both transgenes were used for the experiments.
Generation of adenoviral vectors
For the generation of recombinant adenoviral genomes, the Ad Easy system was employed which allows production of homogeneous adenoviruses without plaque purification. 26 Recombinant adenoviral genomes were obtained by homologous recombination of the respective shuttle plasmid pAdbiluc and adenoviral backbone plasmid pAdEasy1 containing an incomplete, E1 and E3-deleted Ad5 genome (Ad5DE1DE3) in E. coli BJ 5183. Recombinant adenoviral genomes were linearized with PacI and transfected into 293 cells. Recombinant adenovirus stocks used were prepared as described; 51 vector stocks for in vivo injections were purified twice in a CsCl gradient and extensively dialyzed before use. For every stock prepared, the amount of adenoviral DNA was determined by spectrophotometric measurement of OD 260 , and the amount of infectious adenoviral particles (i.u.) was determined by serial dilutions on 293 cells. After 36 to 48 h, cells were fixed, the cytopathic effect was determined and immunofluorescence staining identified infected cells using a FITC-conjugated anti-Ad5-hexon antibody (antibody K6100, DakoCytomation, Glostrup, Denmark).
Infection with adenoviral vectors
An appropriate number of adenovirus i.u. was added in 200 ml culture medium to 2.5 Â 10 5 cells. Following overnight incubation, cells were washed with PBS and 500 ml fresh medium was added and supplemented with 1 mg/ml Dox (Sigma-Aldrich, Taufkirchen, Germany). Per animal, 2.5 Â 10 9 i.u. of purified and dialyzed Adbiluc, Adbiluc2 or Adbiluc-GFP, or 2 Â 10 8 i.u. of Adbiluc-mIFNa, -b or -g, was diluted with PBS to obtain a total volume of 150 ml. If desired, animals were supplemented with 2 mg/ml of Dox in their drinking water containing 5% sucrose. Water supply was renewed every 3 days throughout the experiment. Local authorities approved all animal experiments, and animals received appropriate humane care.
Reporter assays
GFP expression was monitored by inverse fluorescence microscopy using a standard FITC-filter set with excitation by blue light (488 nm). Tissue sections (12-15 mm) were prepared from tissues fixed in 4% paraformaldehyde/0.1 M PBS (pH 7.4) using a vibratome (Microtom VT 1000S, Leica, Bensheim, Germany). Luciferase activity was determined from whole cell extracts essentially as described before, 6 using 0.5 mM firefly D-luciferin (AppliChem, Darmstadt, Germany) as substrate. Luciferase activity is given as RLU per microgram of total protein. Protein content of the lysate was determined using a Bradford assay (Bio-Rad, Hercules, CA, USA).
Analysis of HBV replication
HBV DNA replicative intermediates were analyzed by Southern blot analysis of total liver DNA, and HBV transcripts were analyzed by Northern blot analysis of liver mRNA using 32 P-labelled DNA probes essentially as described before. 48 HBV viremia was determined by real-time PCR (see below).
Imaging bioluminescence in vivo
Bioluminescence in living mice was monitored essentially as described before. 10 Mice anesthesized with avertin were injected intraperitoneally with an aqueous solution of luciferin (100 mg/g body weight) and placed into a light-tight chamber on their backs to visualize light emitted from the liver by a photon-counting camera (2-stage ICCD C2400-47) fitted with a Nikon lens (35 mm/fl.2) and a computer with image analysis capabilities. 34 Body images were recorded as references under daylight. Approximately 5 min after luciferin injection, the chamber was closed and the photoncounting program was initiated for periods of 0.5 to 2 min. Photons were collected over time, and generated images were converted to pseudocolor and digitized with the Argus 20 image processor (Hamamatsu, Hamamatsu, Japan).
Real-time PCR detection of HBV DNA and IP-10 and 2 0 5 0 OAS transcripts Liver samples were collected in RNAlater (Ambion, Austin, TX, USA), and stored at À201C until analysis. In all, 25 mg tissue was disrupted by one run with the RiboLyser (ThermoHYBAID, Heidelberg) in lysing matrix 'D' tubes (Q-BIOgen, Heidelberg) containing 400 ml lysis buffer from the MagnaPure mRNA Isolation Kit II (ROCHE Diagnostics, Mannheim). Lysates were centrifuged for 1 min at 13 000 r.p.m. In all, 300 ml of the cleared lysate was collected and mixed with 600 ml capture buffer containing oligo-dT. After centrifugation at 13 000 r.p.m. for 5 min, 880 ml of this mix was used to isolate mRNA with the MagnaPure-LC device. mRNA was eluted in 50 ml volume. An aliquot of 8.2 ml RNA was reverse transcribed using AMV-RT and oligo-(dT) as primer (First Strand cDNA synthesis kit, Roche). cDNA was diluted to a final volume of 500 ml and stored at À201C until PCR analysis. IP-10 and 2 0 5 0 OAS-specific primer sets optimized for the LightCycler (RAS, Mannheim, Germany) were purchased from SEARCH-LC GmbH, Heidelberg, and used according to the protocol provided in the parameter specific kits.
All PCRs were performed with the LightCycler FastStart DNA Sybr Green mix. To control for specificity of the amplification products, melting curve analysis was performed. The copy number was calculated from a standard curve, obtained by plotting known input concentrations of four different plasmids at log dilutions to the PCR-cycle number (CP) at which the detected fluorescence intensity reaches a fixed value. This approach dramatically reduced variations due to handling errors over several logarithmic dilution steps.
To correct for differences in the content of total RNA, calculated copy numbers were normalized to the average expression of two housekeeping genes, GAPDH and HPRT. Values were thus given as input adjusted copy number per microliter of cDNA.
HBV-DNA was extracted from mouse sera using the DNeasy Kit (Quiagen, Hilden, Germany). HBV DNA was amplified using the LightCycler FastStart DNA Sybr Green mix and primers HBV1745 (5 0 -gttgcccgtttgtcct ctaattc-3 0 ) and HBV1844 (5 0 -ggagggatacatagaggttccttga-3 0 ), and quantified relative to an external plasmid standard.
mIFNg ELISA
Murine IFNg was determined in appropriately diluted cell culture supernatant using a commercially available ELISA (Pharmingen, Heidelberg, Germany) according to the manufacturer's instructions.
Alanin transaminase
Alanin transaminase (ALT) level was determined in 36 ml mouse serum using specific bioreaction strips on a Reflovet s Plus reader (Roche Applied Science) according to the manufacturer's instructions.
